Literature DB >> 17114425

A novel E3 ubiquitin ligase substrate screen identifies Rho guanine dissociation inhibitor as a substrate of gene related to anergy in lymphocytes.

Leon Su1, Neil Lineberry, Yul Huh, Luis Soares, C Garrison Fathman.   

Abstract

Ubiquitination of eukaryotic proteins regulates a broad range of cellular processes, including regulation of T cell activation and tolerance. We have previously demonstrated that gene related to anergy in lymphocytes (GRAIL), a ring finger ubiquitin E3 ligase, is required for the induction of T cell anergy; however, the substrate(s) for GRAIL E3 ligase activity is/are unknown. In this study, we report a novel prokaryotic system developed to screen for substrates of E3 ligases. Using this screen, Rho guanine dissociation inhibitor (RhoGDI) was identified as a potential substrate of GRAIL. GRAIL was subsequently demonstrated to bind and ubiquitinate RhoGDI, although GRAIL-mediated ubiquitination of RhoGDI did not result in proteosomal degradation. Expression of GRAIL in T cells resulted in specific inhibition of RhoA GTPase activation; activation of Rac1, cdc42, and Ras GTPases were not affected. Interestingly, stable T cell lines expressing dominant-negative RhoA mimicked the GRAIL-mediated IL-2 inhibition phenotype, and T cells expressing constitutively active RhoA were able to overcome GRAIL-mediated inhibition of IL-2 expression. These findings validate our prokaryotic screen as a method of identifying substrates for ubiquitin E3 ligases and suggest a role for Rho effector molecules in T cell anergy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17114425     DOI: 10.4049/jimmunol.177.11.7559

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  GRAIL (gene related to anergy in lymphocytes) regulates cytoskeletal reorganization through ubiquitination and degradation of Arp2/3 subunit 5 and coronin 1A.

Authors:  Daiju Ichikawa; Miho Mizuno; Takashi Yamamura; Sachiko Miyake
Journal:  J Biol Chem       Date:  2011-10-20       Impact factor: 5.157

2.  Ubiquitination: Added complexity in Ras and Rho family GTPase function.

Authors:  Michelle de la Vega; James F Burrows; James A Johnston
Journal:  Small GTPases       Date:  2011-07-01

Review 3.  GRAIL: a unique mediator of CD4 T-lymphocyte unresponsiveness.

Authors:  Chan C Whiting; Leon L Su; Jack T Lin; C Garrison Fathman
Journal:  FEBS J       Date:  2010-11-16       Impact factor: 5.542

Review 4.  Transcriptional regulation of T cell tolerance.

Authors:  Sanmay Bandyopadhyay; Noemí Soto-Nieves; Fernando Macián
Journal:  Semin Immunol       Date:  2007-03-26       Impact factor: 11.130

Review 5.  Ubiquitylation in innate and adaptive immunity.

Authors:  Vijay G Bhoj; Zhijian J Chen
Journal:  Nature       Date:  2009-03-26       Impact factor: 49.962

6.  Gene related to anergy in lymphocytes (GRAIL) expression in CD4+ T cells impairs actin cytoskeletal organization during T cell/antigen-presenting cell interactions.

Authors:  Jill M Schartner; William T Simonson; Sarah A Wernimont; Lauren M Nettenstrom; Anna Huttenlocher; Christine M Seroogy
Journal:  J Biol Chem       Date:  2009-10-15       Impact factor: 5.157

7.  Ligand-switchable substrates for a ubiquitin-proteasome system.

Authors:  Emily L Egeler; Lorenz M Urner; Rishi Rakhit; Corey W Liu; Thomas J Wandless
Journal:  J Biol Chem       Date:  2011-07-15       Impact factor: 5.157

Review 8.  Ubiquitin Ligases in Cancer Immunotherapy - Balancing Antitumor and Autoimmunity.

Authors:  Yu Fujita; Roberto Tinoco; Yan Li; Daniela Senft; Ze'ev A Ronai
Journal:  Trends Mol Med       Date:  2019-03-18       Impact factor: 11.951

Review 9.  Induction and stability of the anergic phenotype in T cells.

Authors:  Rut Valdor; Fernando Macian
Journal:  Semin Immunol       Date:  2013-11-05       Impact factor: 11.130

10.  IL-2 signaling prevents T cell anergy by inhibiting the expression of anergy-inducing genes.

Authors:  Myrianne Duré; Fernando Macian
Journal:  Mol Immunol       Date:  2008-11-05       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.